Biontech Se

General

Total Cases10
Active Cases7
Patents100
TypeOperating Company
Elite Ratings
--

Ratings

Experience
Grade
Trend
DCT
--
--
--
PTAB
L2
B
CAFC
--
--
--

Analytics

Cases

Litigated Patents

Ratings Trends

Recent Dockets

Entered
Case
Description
09/16/24
MOTIONS REFERRED to Magistrate Judge: [390] MOTION to Strike Counterclaim Defendants' "Supplemental Identification of Seven Prior Art-Based Invalidity Arguments Per Asserted Claim" (epri, ) (Entered: 09/16/2024)
09/16/24
MOTIONS REFERRED to Magistrate Judge: [390] MOTION to Strike Counterclaim Defendants' "Supplemental Identification of Seven Prior Art-Based Invalidity Arguments Per Asserted Claim" (epri, ) (Entered: 09/16/2024)
09/12/24
Request for Hearing by CureVac SE, CureVac Manufacturing GmbH, CureVac SE re [390] MOTION to Strike Counterclaim Defendants' "Supplemental Identification of Seven Prior Art-Based Invalidity Arguments Per Asserted Claim" (Joint Request for Oral Argument) (Erbach, John) (Entered: 09/12/2024)
09/12/24
Request for Hearing by CureVac SE, CureVac Manufacturing GmbH, CureVac SE re [390] MOTION to Strike Counterclaim Defendants' "Supplemental Identification of Seven Prior Art-Based Invalidity Arguments Per Asserted Claim" (Joint Request for Oral Argument) (Erbach, John) (Entered: 09/12/2024)
09/11/24
REPLY to Response to Motion re [390] MOTION to Strike Counterclaim Defendants' "Supplemental Identification of Seven Prior Art-Based Invalidity Arguments Per Asserted Claim" (REDACTED VERSION) filed by CureVac SE, CureVac Manufacturing GmbH, CureVac SE. (Attachments: # [1] Exhibit A, # [2] Exhibit B (UNDER SEAL), # [3] Exhibit C, # [4] Exhibit D (UNDER SEAL), # [5] Exhibit E (UNDER SEAL))(Erbach, John) (Entered: 09/11/2024)
09/11/24
REPLY to Response to Motion re [390] MOTION to Strike Counterclaim Defendants' "Supplemental Identification of Seven Prior Art-Based Invalidity Arguments Per Asserted Claim" (REDACTED VERSION) filed by CureVac SE, CureVac Manufacturing GmbH, CureVac SE. (Attachments: # [1] Exhibit A, # [2] Exhibit B (UNDER SEAL), # [3] Exhibit C, # [4] Exhibit D (UNDER SEAL), # [5] Exhibit E (UNDER SEAL))(Erbach, John) (Entered: 09/11/2024)
09/11/24
Sealed Response/Reply/Opposition re [409] MOTION to Seal Unredacted Reply and Exhibits B, D and E Thereto. (Attachments: # [1] Exhibit B (UNDER SEAL), # [2] Exhibit D (UNDER SEAL), # [3] Exhibit E (UNDER SEAL))(Erbach, John) (Entered: 09/11/2024)
09/11/24
Sealed Response/Reply/Opposition re [409] MOTION to Seal Unredacted Reply and Exhibits B, D and E Thereto. (Attachments: # [1] Exhibit B (UNDER SEAL), # [2] Exhibit D (UNDER SEAL), # [3] Exhibit E (UNDER SEAL))(Erbach, John) (Entered: 09/11/2024)
09/11/24
Notice of Filing Sealing Motion LCvR5(C) by CureVac SE, CureVac Manufacturing GmbH, CureVac SE re [409] MOTION to Seal Unredacted Reply and Exhibits B, D and E Thereto (Erbach, John) (Entered: 09/11/2024)
09/11/24
Notice of Filing Sealing Motion LCvR5(C) by CureVac SE, CureVac Manufacturing GmbH, CureVac SE re [409] MOTION to Seal Unredacted Reply and Exhibits B, D and E Thereto (Erbach, John) (Entered: 09/11/2024)